7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
1/22
BUSINESS INSIDER
Inside healthcare giant Johnson & Johnson
Source: AP Images
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
2/22
This is Johnson & Johnson a $188 billion business thattouches more than one billion people every day J&J employs 129,000 people, with headquarters in N.J. Founded in 1886 The company is made up of 3 main business lines:
Pharmaceuticals Medical Devices Consumer Healthcare
Fiscal 2011 Segment Sales:
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
3/22
Johnson & Johnson entered U.S. homes on the back of itsfamous commitment to doctors, nurses, and its patients,putting them above shareholders (written in 1943)
Source: Johnson & Johnson
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
4/22
But J&J is very different todaythan when it drew up that credo
J&Js total sales in 2011
J&Js net income in 1980
J&Js total sales in 1980
$0.4Billion
$4.84Billion
$65.03Billion
Source: Johnson & Johnson
$9.67Billion J&Js net income in 2011
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
5/22
Today J&J is made up of more than 250 operatingsubsidiaries. Take a look at some of the businesses J&Joperates in.
(We should note these are just the U.S. subsidiaries)
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
6/22
J&J revenues now top $16 billion a quarter but havebeen range bound since the financial crisis began.
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
7/22
J&J has diversified its sales channels generatinga larger share of revenue from outside the U.S.
Asias importance has magnified, now rivaling Europe with 19% Latin America has also picked up 5 points over the past eight year
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
8/22
But even as the company has grown sales, massivesettlements have hit earnings
In 2011, net income fell 27 percent (to $9.6B) when includingcharges related to product liability, litigation settlements, and a
Hip recall program
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
9/22
Americans know Johnson and Johnsons for itsiconic consumer healthcare business
Flagship products include Listerine, Tylenol, Neutrogena skin care, andBand-Aids
The division booked $14.9 billion in sales, making it the 6th largestconsumer healthcare business in the world.
Image: Johnson & Johnson
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
10/22
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
11/22
But consumer healthcare isnt the companysbread and butter. That would be itspharmaceuticals unit
Sales reached $24.4 billion in 2011, an 8.8 percent increase over 2010. That led to $6.4 billion in operating profit, 51.8 percent of Johnson and
Johnsons total profit for the year.
Image: Wikimedia Commons
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
12/22
(Dollars in Millions) 2011 2010 2009 % Change 11vs. 10
% Change 10vs. 09
Remicade (infliximab) $5,492 $4,610 $4,304 19.1% 7.1
Procrit/Eprex (Epoetinalfa)
$1,623 $1,934 $2,245 (16.1) (13.9)
Risperdal/Consta(risperidone)
$1,583 $1,500 $1,425 5.5 15.8
Velcade(bortezomib) $1,274 $1,080 $933 18 15.8
Concerta(methylphenidate)
$1,268 $1,319 $1,326 (3.9) (0.5)
Prezista (darunavir) $1,211 $857 $592 41.3 44.8
Aciphex/Pariet(rabeprazole sodium)
$975 $1,006 $1,096 (3.1) (8.2)
Levaquin/Floxin(levofloxacin/ofloxacin)
$623 $1,357 $1,550 (54.1) (12.5)
Other pharmaceuticals $10,319 $8,733 9,049 18.2 (3.5)
Total $24,368 $22,396 $22,520 8.8% (0.6)
Driving pharma sales are drugs like Remicade, Risperdal,and Levaquin
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
13/22
Even with those impressive sales figures, J&J faces hugegeneric risk. When Levaquin lost exclusivity, salesplummeted more than 50 percent in one year
$0.0
$0.5
$1.0
$1.5
$2.0
$2.5
$3.0
$3.5
$4.0
2004 2005 2006 2007 2008 2009 2010 2011
Procrit Levaquin/Floxin Topamax Duragesic
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
14/22
To continue to drive top line results, J&J invested morethan $7.5 billion in research and development last year
Johnson spent $5.13 billion, or 71.9 percent of its total research anddevelopment spend, towards its prescription drug pipeline.
That paid dividends last year with the FDA approval of Xarelto, an anti-coagulant. Thomson Reuters estimates that the drug will book $2.2billion in sales by 2014.
Other recent approvals include Edurant in the U.S. and EU for HIV,Zytiga for prostate cancer, and Incivo for Hepatitis C in the EU.
Potentially significant unapproved drugs in Johnson and Johnsonspipeline include Canagliflozin for Type 2 Diabetes, Yondelis for softtissue sarcoma, and Prezista for HIV.
Image: Bristol Meyers
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
15/22
Last of the three divisions is its medical device unit,the largest device business in the world, with 2011sales of $25.8 billion
The largest franchises are DePuy Orthopedics and Ethicon Endo-Surgery, which manufactures tools for minimally invasive surgery.
DePuy purchased Synthes, another orthopedics company, as part ofan ongoing effort to rebrand after a 2010 recall of hip replacements.
Source: Company Filings
Sutures/woundclosure, $4.9
Diabetes Care, $2.6
Orthopedics, $5.8
CardiovascularCare, $2.3
Vision Care, $2.9
Diagnostics, $2.2
Non-Invasive
Surgery, $5.1
Sales in Billions
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
16/22
The device division, formerly the most profitable, wasnegatively impacted by a 2010 recall of hip replacements
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000
$7,000
$8,000
$9,000
2008 2009 2010 2011
Consumer Pharmaceutical Devices and diagnostics
Profit Generation by Division
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
17/22
Nonetheless, its still the largest medical devicemanufacturer in the world, bigger than Abbott, Baxter andPhillips combined
$0 $5 $10 $15 $20 $25 $30
Johnson and Johnson
GE Healthcare
Medtronic
Siemens Healthcare
Phillips Healthcare
Baxter international
Abbott Laboratories
Medical Sales (In Billions)
Source: Company Filings
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
18/22
To generate those sales, J&J spends more than $2.6billion on marketing globally each year, making itone of the largest advertisers
Source: Nielsen
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
19/22
Most analysts believe J&Js stock price will appreciatefrom its current $68 level with some setting targets ashigh as $90 a share
Jefferies: Buy with $75 P.T.
Barclays: Overweight with $75 P.T.
J.P. Morgan: Overweight with $74 P.T.
Goldman Sachs: Neutral with $72 P.T.
Deutsche Bank: Hold with $69 P.T.
Piper Jaffray: Neutral with $68 P.T.
LOW MEDIAN HIGH
$65 $72 $90
Source: Bloomberg
Snapshot:
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
20/22
But not everyone is so bullish. As Morgan Stanley notes,the firm has fallen below peers in the S&P 500
J&J needs to make more aggressive changes to its businessmodel to avoid another three years of underperformance, inour view. Since the beginning of 2010, J&J has returned only2%, falling 8% short of the DRG pharma index and 23% short ofS&P 500 returns. We see the key drivers of weak stock
performance as (i) soft revenue growth, (ii) lack of marginexpansion, and (iii) dilutive capital deployment. Doing thingsthe J&J way has not recently created value forshareholders, and negative structural shifts in the healthcarelandscape may make outperformance even morechallenging over the next several years.
Morgan Stanley
Image: Mario Tama/Getty Images
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
21/22
Some of that negativity is also do to headlines which haveplagued the company, which recently include:
A tentative shareholder settlement to a lawsuit allegingmanagement failed to fix serious problems for manyyears
Shoddy manufacturing Illegal kickbacks to boost sales Improper marketing of drugs for unapproved uses
Source: Washington Post, The New York Times, AdAge
7/31/2019 Johnson & Johnson: The $188 Billion Company That Sells More Than Just Band-Aids And Shampoo
22/22
BUSINESS INSIDERwww.businessinsider.com
To contact the reporters on this, [email protected]